About this trial
The purpose of this trial is to determine the safety and efficacy of the drug copanlisib and the optimum dose when used with trastuzumab emtansine (T-DM1). It will also establish how well copanlisib works in combination with trastuzumab emtansine (T-DM1) to treat anti HER2-therapy resistant breast cancer. The study will also be used to learn more about this new drug and this type of cancer.
Advanced HER2-positive (HER2+) Breast Cancer
Where’s this trial being run?Beaumont Hospital, Cork University Hospital, and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera).
|Principal Investigator:||Prof Bryan Hennessy (Beaumont Hospital)|
Cancer Trials Ireland
|Global Recruitment Target:||24|
|Ireland Recruitment Target:|